Skip to main content

IN8bio, Inc. (INAB)

NASDAQ: INAB · IEX Real-Time Price · USD
7.31 0.31 (4.43%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap137.10M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out18.75M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,980
Open7.40
Previous Close7.00
Day's Range7.30 - 7.75
52-Week Range6.10 - 10.32
Betan/a
Analystsn/a
Price Target15.50 (+112.0%)
Est. Earnings DateNov 5, 2021

About INAB

IN8bio is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a funct...

IndustryBiotechnology
IPO DateJul 30, 2021
CEOWilliam Ho
Employees13
Stock ExchangeNASDAQ
Ticker SymbolINAB
Full Company Profile

Financial Performance

Financial Statements

News

IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies u...

2 weeks ago - GlobeNewsWire

IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Confer...

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies ut...

3 weeks ago - GlobeNewsWire

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leuke...

The first cohort has completed dosing with IN8bio's donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs) o...

1 month ago - GlobeNewsWire

IN8bio Announces Pricing of Initial Public Offering

NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell ther...

1 month ago - GlobeNewsWire

IN8bio Launches Proposed Initial Public Offering

NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery...

2 months ago - GlobeNewswire

IN8bio IPO Registration Document (S-1)

IN8bio, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

4 months ago - SEC

After name change and dropped IPO, IN8bio tries again to boost its cancer pipeline

IN8bio has trod an unusual path to an IPO but now has revived its once-dropped attempt.

5 months ago - FierceBiotech